Board Code: 300759
Board Abbreviation: Kanglonghua
Announcement Number: 2026-052
Kanglonghua (Beijing) New Pharmaceutical Technology Co., Ltd.
Resolution Announcement of the Second Meeting of the Fourth Board of Directors
The Company and all members of the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and there are no false records, misleading statements, or major omissions.
I. Convening of the Board Meeting
The Second Meeting of the Fourth Board of Directors of Kanglonghua (Beijing) New Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") was held via communication on July 24, 2026. The meeting notice and materials were sent to all directors via email on July 17, 2026. 8 directors were eligible to attend, and 8 directors actually attended. The meeting was chaired by Dr. Boliang Lou, and the Company's Secretary of the Board attended the meeting. The convening and holding of this meeting comply with the "Company Law of the People's Republic of China" (hereinafter referred to as the "Company Law") and other relevant laws, administrative regulations, departmental rules, normative documents, and the Articles of Association.
II. Deliberation of the Board Meeting
The attending directors deliberated and approved the following proposals by signed ballot:
(I) Approval of the "Proposal on the 2026 H-Share Incentive Trust Plan"
To ensure the continuity, compliance, and operability of the Company's equity incentive mechanism, and to fully mobilize employees' enthusiasm and creativity, effectively enhance the cohesion of the core team and the core competitiveness of the enterprise, and promote the sustained, stable, and high-quality development of the Company, the Company proposes to formulate and implement the "2026 H-Share Incentive Trust Plan" (hereinafter referred to as the "Plan"). The total number of H shares under the Plan shall not exceed 28,000,000 shares. The source of the shares shall be the H shares repurchased by the Company from the secondary market from time to time and the newly issued H shares by the Company under the Plan from time to time. The Plan shall be valid for ten years from the date of adoption. The terms of the Plan comply with Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.
The Plan shall take effect after being approved by a special resolution of the shareholders' meeting. The Board of Directors will also request the shareholders' meeting to authorize the Board of Directors and its authorized personnel to manage the Plan.
The "2026 H-Share Incentive Trust Plan" needs to be submitted to The Stock Exchange of Hong Kong Limited for review. After The Stock Exchange of Hong Kong Limited confirms the content of the Plan, the full text of the "2026 H-Share Incentive Trust Plan" will be disclosed simultaneously with the notice of the shareholders' meeting. Investors are advised to pay attention to subsequent announcements.
This proposal has been reviewed and approved by the first meeting of the Remuneration and Assessment Committee of the Fourth Board of Directors.
Voting results: 8 votes in favor, 0 votes against, 0 abstentions.
This proposal needs to be submitted to the shareholders' meeting for deliberation.
(II) Approval of the "Proposal on Authorizing the Board of Directors to Repurchase Company H Shares by Shareholders' Meeting"